OBJECTIVES: This study was designed to establish clinical outcomes after aortic valve replacement (AVR) with On-X bileaflet mechanical heart valve. METHODS: Between 2006 and 2014, AVR was performed to 686 patients. Of them, 78 patients using On-X valve were enrolled. The mean age was 65 ± 11 years (ranged 33-85); 65% were men; and 81% were in sinus rhythm preoperatively. Calcific or degenerative tricuspid aortic valve was present in 73%. Concomitant procedures included coronary artery bypass grafting (22%), Bentall (8%), mitral valve procedure (3%) and other (9%). They postoperatively received lower dose warfarin [international normalized ratio (INR), 1.5-2.0] and 100 mg aspirin daily. The follow-up duration averaged 5 years (386.6 patient-years). The follow-up rate was 97.3%. RESULTS: In-hospital mortality rates were 3.8% (n = 3). Late mortality rates were 2.6% per patient-years (n = 10). Five-year Kaplan-Meier survival rates were 84%. Freedom from major adverse valve-related stroke and cerebral bleeding events was 93.3% (n = 5, 1.29% per patient-years) and 98.6% (n = 1, 0.26% per patient-years, mild subdural hematoma). The incidence of stroke was two patients of transient ischemic attack, two patients of paralytic event, one patient of asymptomatic stroke (self-interruption of anticoagulation). The median INR was 1.92 ± 0.53, ranged from 1.00 to 8.98 (n = 1181) and 51% of all measured INR values were in the therapeutic range of 1.5-2.0. CONCLUSIONS: AVR using On-X valve with low target INR regimen and low-dose aspirin resulted in a significantly low risk of bleeding.
OBJECTIVES: This study was designed to establish clinical outcomes after aortic valve replacement (AVR) with On-X bileaflet mechanical heart valve. METHODS: Between 2006 and 2014, AVR was performed to 686 patients. Of them, 78 patients using On-X valve were enrolled. The mean age was 65 ± 11 years (ranged 33-85); 65% were men; and 81% were in sinus rhythm preoperatively. Calcific or degenerative tricuspid aortic valve was present in 73%. Concomitant procedures included coronary artery bypass grafting (22%), Bentall (8%), mitral valve procedure (3%) and other (9%). They postoperatively received lower dose warfarin [international normalized ratio (INR), 1.5-2.0] and 100 mg aspirin daily. The follow-up duration averaged 5 years (386.6 patient-years). The follow-up rate was 97.3%. RESULTS: In-hospital mortality rates were 3.8% (n = 3). Late mortality rates were 2.6% per patient-years (n = 10). Five-year Kaplan-Meier survival rates were 84%. Freedom from major adverse valve-related stroke and cerebral bleeding events was 93.3% (n = 5, 1.29% per patient-years) and 98.6% (n = 1, 0.26% per patient-years, mild subdural hematoma). The incidence of stroke was two patients of transient ischemic attack, two patients of paralytic event, one patient of asymptomatic stroke (self-interruption of anticoagulation). The median INR was 1.92 ± 0.53, ranged from 1.00 to 8.98 (n = 1181) and 51% of all measured INR values were in the therapeutic range of 1.5-2.0. CONCLUSIONS: AVR using On-X valve with low target INR regimen and low-dose aspirin resulted in a significantly low risk of bleeding.
Authors: K Hammermeister; G K Sethi; W G Henderson; F L Grover; C Oprian; S H Rahimtoola Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: J Am Coll Cardiol Date: 2006-08-01 Impact factor: 24.094
Authors: Cary W Akins; D Craig Miller; Marko I Turina; Nicholas T Kouchoukos; Eugene H Blackstone; Gary L Grunkemeier; Johanna J M Takkenberg; Tirone E David; Eric G Butchart; David H Adams; David M Shahian; Siegfried Hagl; John E Mayer; Bruce W Lytle Journal: J Thorac Cardiovasc Surg Date: 2008-04 Impact factor: 5.209
Authors: V Chan; W R E Jamieson; E Germann; F Chan; R T Miyagishima; L H Burr; M T Janusz; H Ling; G J Fradet Journal: J Thorac Cardiovasc Surg Date: 2006-06 Impact factor: 5.209
Authors: Eric G Butchart; Nicola Payne; Hui-Hua Li; Keith Buchan; Kayapanda Mandana; Gary L Grunkemeier Journal: J Thorac Cardiovasc Surg Date: 2002-04 Impact factor: 5.209
Authors: Kathleen W McNicholas; Tom D Ivey; Jacques Metras; Szabolcs Szentpetery; Steven W Marra; Roy G Masters; Emery W Dilling; Mark S Slaughter; Michael J Mack Journal: J Heart Valve Dis Date: 2006-01
Authors: Martijn W A van Geldorp; W R Eric Jamieson; A Pieter Kappetein; Jian Ye; Guy J Fradet; Marinus J C Eijkemans; Gary L Grunkemeier; Ad J J C Bogers; Johanna J M Takkenberg Journal: J Thorac Cardiovasc Surg Date: 2009-02-25 Impact factor: 5.209
Authors: John Puskas; Marc Gerdisch; Dennis Nichols; Reed Quinn; Charles Anderson; Birger Rhenman; Lilibeth Fermin; Michael McGrath; Bobby Kong; Chad Hughes; Gulshan Sethi; Michael Wait; Tomas Martin; Allen Graeve Journal: J Thorac Cardiovasc Surg Date: 2014-01-12 Impact factor: 5.209